ArticleCirculation reports2026
Association Between Body Mass Index and Cardiac Dysfunction During Human Epidermal Growth Factor Receptor 2 Inhibitor Therapy for Breast Cancer.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The administration of human epidermal growth factor receptor 2 inhibitors (HER2i) has improved the survival of patients with breast cancer; however, cancer therapy-related cardiac dysfunction (CTRCD) has been reported as an adverse effect. In this study we evaluated the incidence of CTRCD associated with HER2i treatment and explored risk factors for a decrease in left ventricular function. Methods and Results: This retrospective study included 94 female patients with breast cancer treated at Kanazawa Medical University Hospital from January 1, 2017, to August 31, 2023. Clinical, hematologic and echocardiographic data were collected. The median pretreatment body mass index (BMI; 22.3 kg/m Conclusions: Low BMI was associated with a greater risk of cardiotoxicity during HER2i treatment. Careful cardiac monitoring is particularly recommended for patients with low BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.